Quick Takeaways:
- Boehringer Ingelheim has received FDA approval for a new Quarterable Snap-Tab design for Previcox (firocoxib) Chewable Tablets, enabling more precise, customizable dosing for dogs based on body weight.
- The double-scored 57 mg and 227 mg tablets can be divided into quarters, allowing veterinarians to prescribe lower doses for dogs as small as 7 lb while offering greater dosing flexibility for osteoarthritis and postoperative pain and inflammation.
- The redesign also supports sustainability, with divided tablets storable for up to one month in their container. New packaging removes cotton and uses an industry-standard bottle to reduce waste and material use, with changes rolling out through 2026–2027.
Why It Matters?
Boehringer Ingelheim’s quarterable Previcox tablets strengthen its differentiation in canine pain management by enabling more precise weight-based dosing and improved flexibility. The sustainability-focused redesign may further enhance brand appeal, supporting veterinarian preference and reinforcing Previcox’s competitiveness against other canine NSAIDs.
Source: PRnewswire
